NYSE:BAX - Baxter International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.29
  • Forecasted Upside: 30.77 %
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.73 (1.22%)

This chart shows the closing price for BAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Baxter International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAX

Analyst Price Target is $79.29
▲ +30.77% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $79.29, with a high forecast of $100.00 and a low forecast of $60.00. The average price target represents a 30.77% upside from the last price of $60.63.

This chart shows the closing price for BAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Baxter International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2022The Goldman Sachs GroupReiterated RatingSell$70.00 ➝ $60.00Low
7/29/2022CowenLower Price Target$95.00 ➝ $70.00Low
7/29/2022CowenLower Price Target$95.00 ➝ $70.00Low
7/29/2022Deutsche Bank AktiengesellschaftLower Price Target$99.00 ➝ $69.00Low
7/29/2022Morgan StanleyLower Price TargetOverweight$86.00 ➝ $72.00Low
7/28/2022CitigroupLower Price Target$82.00 ➝ $74.00Low
7/18/2022Stifel NicolausLower Price Target$85.00 ➝ $75.00Low
7/15/2022Morgan StanleyLower Price TargetOverweight$95.00 ➝ $86.00Low
6/24/2022JPMorgan Chase & Co.Lower Price TargetOverweight$90.00 ➝ $78.00Low
6/24/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$71.00Low
5/23/2022Morgan StanleyLower Price TargetOverweight$100.00 ➝ $95.00Low
5/17/2022CitigroupLower Price TargetBuy$98.00 ➝ $85.00N/A
4/29/2022Raymond JamesLower Price Target$96.00 ➝ $85.00Low
4/4/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$88.00 ➝ $77.00High
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$100.00Low
2/18/2022Wells Fargo & CompanyLower Price TargetOverweight$95.00 ➝ $93.00High
2/18/2022Stifel NicolausBoost Price TargetBuy$90.00 ➝ $91.00High
2/18/2022UBS GroupBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $91.00Low
2/18/2022Morgan StanleyLower Price TargetOverweight$110.00 ➝ $105.00Low
2/18/2022Raymond JamesLower Price TargetOutperform$99.00 ➝ $96.00Low
2/18/2022KeyCorpLower Price TargetOverweight$98.00 ➝ $95.00Medium
2/11/2022The Goldman Sachs GroupInitiated CoverageNeutral$91.00Medium
1/7/2022CitigroupInitiated CoverageBuy$101.00Low
1/7/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$86.00 ➝ $110.00Low
1/4/2022Raymond JamesBoost Price TargetOutperform$93.00 ➝ $99.00High
1/4/2022KeyCorpBoost Price TargetOverweight$92.00 ➝ $98.00High
12/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight ➝ OverweightMedium
10/29/2021Morgan StanleyLower Price TargetEqual Weight$90.00 ➝ $86.00High
9/21/2021Raymond JamesInitiated CoverageBuy$93.00Low
9/13/2021CowenUpgradeMarket Perform ➝ Outperform$98.00Low
9/5/2021SVB LeerinkReiterated RatingBuyLow
9/3/2021BarclaysUpgradeEqual Weight ➝ Overweight$93.00 ➝ $100.00Low
8/3/2021The Goldman Sachs GroupLower Price TargetNeutral$93.00 ➝ $80.00Low
8/2/2021KeyCorpLower Price TargetOverweight$94.00 ➝ $92.00Low
7/29/2021Stifel NicolausLower Price TargetBuy$95.00 ➝ $90.00Low
7/29/2021Piper SandlerLower Price TargetNeutral$85.00 ➝ $82.00Low
5/24/2021BarclaysInitiated CoverageEqual Weight$93.00Low
4/30/2021CitigroupBoost Price Target$94.00 ➝ $98.00Low
4/29/2021Piper SandlerBoost Price TargetNeutral ➝ In-Line$80.00 ➝ $85.00Low
3/18/2021OppenheimerReiterated RatingBuyLow
2/5/2021Credit Suisse GroupLower Price TargetOutperform$99.00 ➝ $95.00Low
2/5/2021Raymond JamesLower Price TargetOutperform$88.00 ➝ $85.00Low
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$100.00 ➝ $80.00Low
1/6/2021UBS GroupDowngradeBuy ➝ Neutral$95.00 ➝ $85.00N/A
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$84.00 ➝ $90.00Low
12/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$96.00 ➝ $85.00Medium
11/2/2020Stifel NicolausLower Price TargetBuy$90.00 ➝ $88.00Low
10/30/2020Morgan StanleyLower Price TargetEqual Weight$90.00 ➝ $84.00Low
10/30/2020KeyCorpLower Price TargetOverweight$98.00 ➝ $94.00Low
10/12/2020Raymond JamesLower Price TargetOutperform$95.00 ➝ $88.00Low
10/9/2020UBS GroupLower Price TargetBuy$98.00 ➝ $96.00Medium
10/1/2020CitigroupUpgradeNeutral ➝ Buy$94.00Medium
9/4/2020ArgusDowngradeBuy ➝ HoldMedium
8/11/2020Credit Suisse GroupReiterated RatingBuy$99.00Low
7/31/2020Credit Suisse GroupReiterated RatingBuy$99.00High
7/31/2020Raymond JamesLower Price TargetOutperform$97.00 ➝ $95.00Medium
7/31/2020Morgan StanleyLower Price TargetEqual Weight$95.00 ➝ $90.00Low
7/30/2020OppenheimerReiterated RatingBuyLow
6/23/2020OppenheimerInitiated CoverageOutperform$100.00Medium
5/1/2020UBS GroupBoost Price TargetBuy$95.00 ➝ $103.00Low
5/1/2020SVB LeerinkBoost Price TargetOutperform$96.00 ➝ $105.00Low
5/1/2020Credit Suisse GroupBoost Price TargetOutperform$97.00 ➝ $99.00Low
5/1/2020KeyCorpBoost Price TargetOverweight$92.00 ➝ $98.00Low
4/30/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $100.00Low
4/28/2020JPMorgan Chase & Co.Boost Price TargetOverweight$94.00 ➝ $96.00Low
4/20/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $104.00Low
4/14/2020BarclaysReiterated RatingHold$84.00High
4/13/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $97.00Low
4/2/2020Wells Fargo & CompanyReiterated RatingBuyHigh
3/27/2020Morgan StanleyBoost Price TargetHold$88.00 ➝ $95.00Low
3/19/2020Stifel NicolausUpgradeHold ➝ Buy$87.00 ➝ $95.00High
3/18/2020Wells Fargo & CompanyLower Price Target$102.00 ➝ $95.00High
3/18/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$109.00 ➝ $99.00High
3/18/2020CitigroupLower Price TargetNeutral$94.00 ➝ $89.00High
3/18/2020Credit Suisse GroupLower Price TargetOutperform$98.00 ➝ $96.00High
3/18/2020Raymond JamesLower Price TargetNeutral ➝ Outperform$95.00 ➝ $90.00High
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$92.00High
3/17/2020SVB LeerinkReiterated RatingOutperformHigh
3/6/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Medium
3/4/2020CitigroupInitiated CoverageNeutral$94.00High
2/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$100.00 ➝ $102.00Low
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$104.00Low
2/6/2020CfraBoost Price TargetHold$87.00 ➝ $93.00Low
1/16/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $100.00Low
1/13/2020UBS GroupReiterated RatingBuy$102.00High
1/2/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
1/2/2020CitigroupUpgradeNeutral ➝ BuyHigh
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$80.00 ➝ $94.00High
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$89.00 ➝ $94.00Low
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $88.00Medium
10/21/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$109.00High
10/8/2019JPMorgan Chase & Co.Set Price TargetBuy$94.00Low
9/10/2019Piper Jaffray CompaniesReiterated RatingBuyN/A
7/26/2019Royal Bank of CanadaSet Price TargetHold$87.00Low
7/26/2019BarclaysSet Price TargetHold$82.00Low
7/26/2019Wells Fargo & CompanySet Price TargetBuy$95.00Low
7/26/2019Raymond JamesBoost Price TargetOutperform$84.00 ➝ $95.00Low
7/26/2019Credit Suisse GroupBoost Price TargetReduce ➝ Outperform$84.00 ➝ $95.00Low
7/26/2019BMO Capital MarketsBoost Price TargetOutperform$95.00Low
7/25/2019Piper Jaffray CompaniesBoost Price TargetOverweight$90.00 ➝ $95.00Low
6/26/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
6/25/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightMedium
6/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $90.00Low
5/13/2019JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $88.00Low
4/22/2019CowenSet Price TargetHold$75.00Low
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$72.00 ➝ $75.00Low
4/3/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $89.00Medium
3/5/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $83.00Low
2/1/2019BarclaysUpgradeUnderweight ➝ Equal Weight$67.00 ➝ $72.00Low
2/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$80.00Low
1/2/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $77.00Low
1/2/2019CitigroupUpgradeNeutral ➝ Buy$69.00 ➝ $76.00Low
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$77.00Medium
12/4/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $76.00High
11/27/2018UBS GroupInitiated CoverageBuy$80.00High
11/13/2018CitigroupLower Price TargetNeutral ➝ Neutral$76.00 ➝ $69.00Medium
11/8/2018Royal Bank of CanadaLower Price TargetPositive ➝ Sector Perform$76.00 ➝ $70.00N/A
11/5/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$75.00 ➝ $66.00Low
11/2/2018ArgusUpgradeHold ➝ Buy$70.00Low
11/1/2018Piper Jaffray CompaniesLower Price TargetOverweight$83.00 ➝ $72.00Low
11/1/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$86.00 ➝ $76.00Medium
11/1/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$90.00 ➝ $77.00Medium
11/1/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$80.00 ➝ $74.00Low
11/1/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$82.00 ➝ $72.00Medium
10/15/2018BarclaysInitiated CoverageUnderweight ➝ Underweight$73.00Medium
10/11/2018Morgan StanleyBoost Price TargetUnderweight$68.00 ➝ $75.00Low
9/4/2018ArgusReiterated RatingHoldLow
7/31/2018CitigroupBoost Price TargetNeutral ➝ Neutral$74.00 ➝ $76.00Medium
7/27/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $83.00Medium
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $85.00High
7/27/2018Royal Bank of CanadaReiterated RatingHold$76.00High
5/31/2018Piper Jaffray CompaniesReiterated RatingOverweight$77.00Medium
5/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$73.00 ➝ $83.00Low
5/17/2018Piper Jaffray CompaniesInitiated CoverageOverweight$77.00Low
4/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$70.00 ➝ $72.00Medium
4/30/2018Stifel NicolausBoost Price TargetHold ➝ Hold$71.00 ➝ $72.00Medium
2/20/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$80.00Low
2/6/2018CitigroupBoost Price TargetNeutral ➝ Neutral$66.00 ➝ $70.00Medium
2/2/2018Royal Bank of CanadaReiterated RatingHold$72.00Medium
2/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$73.00 ➝ $77.00Medium
2/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $77.00Medium
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$73.00Medium
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$71.00Medium
1/2/2018Bank of AmericaUpgradeNeutral ➝ BuyHigh
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
11/22/2017Bank of AmericaReiterated RatingHoldN/A
11/22/2017Royal Bank of CanadaReiterated RatingHold$66.00N/A
10/26/2017Stifel NicolausReiterated RatingHold$65.00N/A
10/26/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $73.00N/A
10/26/2017Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $62.00N/A
10/15/2017CowenSet Price TargetHold$68.00N/A
10/13/2017CowenReiterated RatingHold ➝ NeutralN/A
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingHold$60.00Low
9/1/2017Royal Bank of CanadaReiterated RatingHold$60.00N/A
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$63.00Low
(Data available from 8/11/2017 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 13 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 8 very positive mentions
  • 36 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 28 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 35 positive mentions
  • 11 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 35 positive mentions
  • 11 negative mentions
  • 0 very negative mentions
Baxter International logo
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $60.63
Low: $59.62
High: $60.66

50 Day Range

MA: $65.53
Low: $57.91
High: $74.47

52 Week Range

Now: $60.63
Low: $57.49
High: $89.70


10,288 shs

Average Volume

3,292,007 shs

Market Capitalization

$30.53 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Baxter International?

The following Wall Street research analysts have issued research reports on Baxter International in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Raymond James, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BAX.

What is the current price target for Baxter International?

14 Wall Street analysts have set twelve-month price targets for Baxter International in the last year. Their average twelve-month price target is $79.29, suggesting a possible upside of 30.8%. Barclays PLC has the highest price target set, predicting BAX will reach $100.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $60.00 for Baxter International in the next year.
View the latest price targets for BAX.

What is the current consensus analyst rating for Baxter International?

Baxter International currently has 1 sell rating, 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BAX will outperform the market and that investors should add to their positions of Baxter International.
View the latest ratings for BAX.

What other companies compete with Baxter International?

Other companies that are similar to Baxter International include DexCom, ResMed, Insulet, Abiomed and Teleflex. Learn More about companies similar to Baxter International.

How do I contact Baxter International's investor relations team?

Baxter International's physical mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier's listed phone number is (224) 948-2000 and its investor relations email address is global_[email protected] The official website for Baxter International is www.baxter.com. Learn More about contacing Baxter International investor relations.